We are pleased to announce that the clinical trial targeting metastatic non-small cell lung cancer (NSCLC) has received official approval.
The approval was granted within 30 business days by the Scientific Centre of Drug and Medical Technology Expertise. Additionally, we are proud to report that the Institutional Review Board (IRB) has provided their approval in just 9 business days.
With look forward to conducting this vital research at the Yeolyan Hematology and Oncology Center. We aim to make meaningful strides in improving outcomes for those affected by NSCLC.
This approval marks a significant milestone in our journey.
Tha Principle Investigator (PI) of the Metastatic Non-Small Cell Lung Cancer Clinical Trial is Dr Samvel Bardakhchyan.
About IMMONC
Immune Oncology Research Institute (IMMONC) is dedicated to advancing research aimed at preventing, treating, and ultimately curing cancer while making these innovations accessible to those who need them. If you're interested in joining our team, please feel free to contact us at [email protected] or at +374-41 310-048